PDE-4 and JAK Inhibitors in Pediatric AD

Panelists discuss how emerging topical therapies targeting PDE-4 and JAK pathways offer new hope for children with atopic dermatitis (AD) by addressing inflammation at the cellular level. These nonsteroidal agents are designed to provide strong anti-inflammatory effects with minimal systemic exposure.

Panelists note that these treatments can help reduce itch, redness, and flare frequency, improving both comfort and skin appearance. Their nonsteroidal nature makes them appealing to caregivers who wish to minimize corticosteroid use, particularly for long-term management.

They also stress the importance of individualized care, noting that while these therapies can be effective across disease severities, clinicians must match the right treatment to each child’s needs. Education about realistic expectations, adherence, and proper application remains essential for success.